NCT06872580View on ClinicalTrials.gov

A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

QLS1209

Levels of QLS1209 will be explored in dose escalation, and determine the maximum tolerated dose.

DRUG

QLS1209

Every 21 days is one cycle.1-3 dose levels of QLS1209 will be explored in dose optimization, and determine the recommended dose (RD) of QLS1209 and evaluate the preliminary anti-tumor activity of QLS1209.

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY